Claude Emond

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/762760/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Brominated flame retardants, a cornelian dilemma. Environmental Chemistry Letters, 2023, 21, 9-14.	8.3	6
2	Regulatory and academic studies to derive reference values for human health: The case of bisphenol S. Environmental Research, 2022, 204, 112233.	3.7	22
3	Chlordecone: development of a physiologically based pharmacokinetic tool to support human health risks assessments. Archives of Toxicology, 2022, 96, 1009-1019.	1.9	6
4	Population-based biomonitoring of exposure to persistent and non-persistent organic pollutants in the Grand Duchy of Luxembourg: Results from hair analysis. Environment International, 2021, 153, 106526.	4.8	29
5	A PBPK model describing the pharmacokinetics of Î ³ -HBCD exposure in mice. Toxicology and Applied Pharmacology, 2021, 428, 115678.	1.3	7
6	Exploring Mechanistic Toxicity of Mixtures Using PBPK Modeling and Computational Systems Biology. Toxicological Sciences, 2020, 174, 38-50.	1.4	18
7	Blood pharmacokinetic of 17 common pesticides in mixture following a single oral exposure in rats: implications for human biomonitoring and exposure assessment. Archives of Toxicology, 2019, 93, 2849-2862.	1.9	9
8	Regulatory identification of BPA as an endocrine disruptor: Context and methodology. Molecular and Cellular Endocrinology, 2018, 475, 4-9.	1.6	83
9	The Influence of Obesity on the Pharmacokinetics of Dioxin in Mice: An Assessment Using Classical and PBPK Modeling. Toxicological Sciences, 2018, 164, 218-228.	1.4	5
10	Exposure to polycyclic aromatic hydrocarbons in women living in the Chinese cities of BaoDing and Dalian revealed by hair analysis. Environment International, 2018, 121, 1341-1354.	4.8	51
11	Physiologically based pharmacokinetic toolkit to evaluate environmental exposures: Applications of the dioxin model to study real life exposures. Toxicology and Applied Pharmacology, 2017, 315, 70-79.	1.3	8
12	Toward a general physiologically-based pharmacokinetic model for intravenously injected nanoparticles. International Journal of Nanomedicine, 2016, 11, 625.	3.3	73
13	A Physiological Pharmacokinetic Model Based on Tissue Lipid Content for Simulating Inhalation Pharmacokinetics of Highly Lipophilic Volatile Organic Chemicals. Toxicology Mechanisms and Methods, 2006, 16, 395-403.	1.3	6
14	Use of a Physiologically Based Pharmacokinetic Model for Rats to Study the Influence of Body Fat Mass and Induction of CYP1A2 on the Pharmacokinetics of TCDD. Environmental Health Perspectives, 2006, 114, 1394-1400.	2.8	64
15	Comparison of the Use of a Physiologically Based Pharmacokinetic Model and a Classical Pharmacokinetic Model for Dioxin Exposure Assessments. Environmental Health Perspectives, 2005, 113, 1666-1668.	2.8	67
16	Physiologically Based Pharmacokinetic Model for Developmental Exposures to TCDD in the Rat. Toxicological Sciences, 2004, 80, 115-133.	1.4	47